139 related articles for article (PubMed ID: 28509593)
1. Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia.
Büttner B; Knoth H; Kramer M; Oertel R; Seeling A; Sockel K; von Bonin M; Stölzel F; Alakel N; Platzbecker U; Röllig C; Ehninger G; Bornhäuser M; Schetelig J; Middeke JM
Leuk Lymphoma; 2017 Dec; 58(12):2865-2874. PubMed ID: 28509593
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan.
Suzuki T; Yamauchi T; Ando K; Nagai T; Kakihana K; Miyata Y; Uchida T; Tabata Y; Ogura M
Jpn J Clin Oncol; 2013 Dec; 43(12):1177-83. PubMed ID: 24130086
[TBL] [Abstract][Full Text] [Related]
3. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Steinherz PG; Shukla N; Kobos R; Steinherz L
Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
[TBL] [Abstract][Full Text] [Related]
4. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
[TBL] [Abstract][Full Text] [Related]
5. Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.
Loeffler C; Kapp M; Grigoleit GU; Mielke S; Loeffler J; Heuschmann PU; Malzahn U; Hupp E; Einsele H; Stuhler G
Leuk Lymphoma; 2015; 56(12):3365-9. PubMed ID: 26014275
[TBL] [Abstract][Full Text] [Related]
6. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
Foster MC; Amin C; Voorhees PM; van Deventer HW; Richards KL; Ivanova A; Whitman J; Chiu WM; Barr ND; Shea T
Leuk Lymphoma; 2012 Jul; 53(7):1331-7. PubMed ID: 22149206
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
Tse E; Leung AY; Sim J; Lee HK; Liu HS; Yip SF; Kwong YL
Ann Hematol; 2011 Nov; 90(11):1277-81. PubMed ID: 21455604
[TBL] [Abstract][Full Text] [Related]
8. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant.
Petri CR; O'Donnell PH; Cao H; Artz AS; Stock W; Wickrema A; Hard M; van Besien K
Leuk Lymphoma; 2014 Dec; 55(12):2866-73. PubMed ID: 24564572
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine Dosing in a Patient With Acute Myeloid Leukemia on Intermittent Hemodialysis: Case Report and Review of the Literature.
Benitez LL; Gharibian K; Frame D; Mody R; Mora E
J Pediatr Hematol Oncol; 2017 Aug; 39(6):481-484. PubMed ID: 28538504
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.
Abbi KK; Rybka W; Ehmann WC; Claxton DF
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):41-6. PubMed ID: 25085441
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
Koh K; Ogawa C; Okamoto Y; Kudo K; Inagaki J; Morimoto T; Mizukami H; Ecstein-Fraisse E; Kikuta A
Int J Hematol; 2016 Aug; 104(2):245-55. PubMed ID: 27086352
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
Jeha S; Razzouk B; Rytting M; Rheingold S; Albano E; Kadota R; Luchtman-Jones L; Bomgaars L; Gaynon P; Goldman S; Ritchey K; Arceci R; Altman A; Stine K; Steinherz L; Steinherz P
J Clin Oncol; 2009 Sep; 27(26):4392-7. PubMed ID: 19652076
[TBL] [Abstract][Full Text] [Related]
13. Clofarabine-based consolidation therapy in AML.
Brower V
Lancet Oncol; 2017 Apr; 18(4):e201. PubMed ID: 28262461
[No Abstract] [Full Text] [Related]
14. Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine.
Knoebel RW; McQuary A; Becker P; Hendrie P; Petersdorf S; Appelbaum FR; Estey E
Leuk Res; 2011 Sep; 35(9):e164-6. PubMed ID: 21684006
[No Abstract] [Full Text] [Related]
15. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
[TBL] [Abstract][Full Text] [Related]
16. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; Cutini I; Longo G; Susini MC; Angelucci E; Bosi A
Am J Hematol; 2012 Dec; 87(12):1047-51. PubMed ID: 23151979
[TBL] [Abstract][Full Text] [Related]
17. Clofarabine: a new treatment option for patients with acute myeloid leukemia.
Larson ML; Venugopal P
Expert Opin Pharmacother; 2009 Jun; 10(8):1353-7. PubMed ID: 19463072
[TBL] [Abstract][Full Text] [Related]
18. The role of Clofarabine in the treatment of adults with acute myeloid leukemia.
Fozza C
Crit Rev Oncol Hematol; 2015 Mar; 93(3):237-45. PubMed ID: 25457773
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.
Jacoby MA; Martin MG; Uy GL; Westervelt P; Dipersio JF; Cashen A; Stockerl-Goldstein K; Vij R; Luo J; Reineck T; Bernabe N; Abboud CN
Am J Hematol; 2014 May; 89(5):487-92. PubMed ID: 24415560
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
Shukla N; Kobos R; Renaud T; Steinherz LJ; Steinherz PG
Pediatr Blood Cancer; 2014 Mar; 61(3):431-5. PubMed ID: 24115731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
